PARP inhibitor combinations in prostate cancer

Polyadenosine-diphosphate-ribose polymerase (PARP) inhibitors cause deoxyribonucleic acid (DNA) damage that can be lethal to cells with deficient repair mechanisms. A number of PARP inhibitors are being tested as treatments for men with prostate cancer, both as monotherapies and in combinations that...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Medical Oncology 2020, Vol.12, p.1758835919897537-1758835919897537
Main Author: Pezaro, Carmel
Format: Article
Language:English
Subjects:
Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology
Deoxyribonucleic acid
DNA
DNA damage
DNA repair
Poly(ADP-ribose) polymerase
Prostate cancer
Ribose
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Polyadenosine-diphosphate-ribose polymerase (PARP) inhibitors cause deoxyribonucleic acid (DNA) damage that can be lethal to cells with deficient repair mechanisms. A number of PARP inhibitors are being tested as treatments for men with prostate cancer, both as monotherapies and in combinations that are based on purported synergies in treatment effect. While the initial single-agent development focused on men with identified deficiencies in DNA-repair pathways, broader patient populations are being considered for combination approaches. This review summarizes the current clinical development of PARP inhibitors and explores the rationale for novel combination strategies.
ISSN:1758-8359
1758-8340
1758-8359
DOI:10.1177/1758835919897537